Less-than-standard treatment in rectal cancer patients: Which patients are at risk?

Journal of the National Medical Association

Volumn 102, Issue 3, 2010, Pages 190-198

  Pisu, Maria ^a   Richardson, Lisa C ^c   Kim, Young Il ^a   Krontiras, Helen ^b   Martin, Michelle Y ^a   Salas, Maribel ^d   Pollack, Lori A ^c  

^a University of Alabama at Birmingham   (United States)

^b Kentucky   (United States)

^c NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^d Safety Assessment US   (United States)

Author keywords

Cancer; Chemotherapy; Rectum; Treatment; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURGERY; COMORBIDITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE DIFFERENCE; RECTUM CANCER; SOCIOECONOMICS; TREATMENT DURATION; UNITED STATES;

EID: 77950624436     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)30525-3     Document Type: Article

References (24)

1. American Cancer Society. Cancer facts and Figures, 2009. Atlanta, GA: American Cancer Society; 2009.
2. American Cancer Society and Alabama Statewide Cancer Registry. Alabama Cancer Facts and Figures 2008. American Cancer Society. http://www.adph.org/ cancer-registry/assets/2008FactsFigures.pdf. Accessed July 31, 2009.
3. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology,™ March 2005.
4. Chu KC, Tarone RE, Chow WH, Hankey BF, Ries LA. Temporal patterns in colorectal cancer incidence, survival, and mortality from 1950 through 1990. J Natl Cancer lnsf. 1994;86(13):997-1006.
5. Rabeneck L, El-Serag HB, Davila JA, Sandler RS. Outcomes of colorectal cancer in the United States: no change in survival (1986-1997). Am J Gastroenterol. 2003;98(2):471-477.
6. Dobie SA, Warren JL, Matthews B, Schwartz D, Baldwin LM, Billingsley K. Survival benefits and trends in use of adjuvant therapy among elderly stage Il and III rectal cancer patients in the general population. Cancer. 2008:112(4):789-799.
7. Fietkau R, Rodel C, Hohenberger W, et al. Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: results of study CAO/ARO/AIO-94. Int J Radiat Oncol Biol Phys. 2007;67(4):1008-1019.
8. Schroen AT, Cress RD. Use of surgical procedures and adjuvant therapy in rectal cancer treatment: a population-based study. Ann Surg. 2001;234(5):641-651.
9. Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB. Who gets adjuvant treatment for stage U and III rectal cancer? Insight from surveillance, epidemiology, and end results-Medicare. J Clin Oncol. 2001;19(17):3712-3718.
10. US Census Bureau. 2000 Census of Population. Available at http://www.cber.cba.edu. Accessed December 20, 2008.
11. Bureau of Health Professions - Health Resources and Services Administration. State Health Workforce Profiles: Highlights-Alabama 2000. http://bhpr.hrsa.gov/healthworkforce/reports/statesummaries/alabama.htm. Accessed December 20, 2008.
12. Ballas LK, Elkin EB, Schrag D, Minsky BD, Bach PB. Radiation therapy facilities in the United States. Int J Radiat Oncol Biol Phys. 2006;66(4):1204-1211.
13. Roetzheim RG, Pal N, Gonzalez EC, Ferrante JM, Van Durme DJ, Krischer JP. Effects of health insurance and race on colorectal cancer treatments and outcomes. Am J Public Health. 2000;90(11):1746-1754.
14. Abraham NS, Gossey JT, Davila JA, Al-Oudat S, Kramer JK. Receipt of recommended therapy by patients with advanced colorectal cancer. Am J Gastroenterol. 2006;101(6):1320-1328.
15. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002;20(5):1192-1202.
16. Thoburn KK, German RR, Lewis M, Nichols PJ, Ahmed F, Jackson-Thompson J. Case completeness and data accuracy in the Centers for Disease Control and Prevention's National Program of Cancer Registries. Cancer. 2007;109(8):1607- 1616.
17. Klabunde CN, Potosky AL, Legier JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258-1267.
18. Ooi BS, Tjandra JJ, Green MD. Morbidities of adjuvant chemotherapy and radiotherapy for resectable rectal cancer: an overview. Dis Colon Rectum. 1999;42(3):403-418. (Pubitemid 29143843)
19. Ramani VS, Gollins SW, Wong H. Weekly fluorouracil at 425 mg/m(2) plus low-dose folinic acid for 24 weeks as adjuvant treatment for colorectal cancer assessment of toxicity and delivery. Clin Oncol (R Coll Radiol). 2006;18(9):649-657.
20. Dobie SA, Baldwin LM, Dominitz JA, Matthews B, Billingsley K, Barlow W. Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst. 2006;98(9):610-619. (Pubitemid 43904844)
21. Neugut Al, Matasar M, Wang X, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol. 2006;24(15):2368-2375. (Pubitemid 46630669)
22. Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicare-linked data. Med Care. 2002:40(8 suppl):IV-49-54.
23. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002:40(8 suppl):IV-55-61.
24. Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003:21(7):1293-1300.■